

LIST OF TABLES

1.1 List of Tables

- Table 1: Initial Presenting Symptoms of Colorectal Cancer
- Table 2: Colorectal Screening FOB Test Participation in Italy by Age and Sex, 2008
- Table 3: TNM Classification System to Stage CRC
- Table 4: Stage Grouping for CRC
- Table 5: Stage II CRC Sub-Divisions
- Table 6: Stage III CRC Sub-Divisions
- Table 7: Stage IV CRC Sub-Divisions
- Table 8: Dukes System of CRC Classification
- Table 9: Treatment Guidelines for Colorectal Cancer
- Table 10: Surgical Options for Colorectal Cancer
- Table 11: Treatment Alternatives for CRC
- Table 12: Incident Cases of Colorectal Cancer, Ages \geq 40 Years, Men and Women, N, 2012-2019
- Table 13: Costs of CRC Diagnosis, Treatment and Care
- Table 14: CRC Screening Test Segmentation
- Table 15: Guaiac Fecal Occult Blood Tests Product Profile
- Table 16: Guaiac FOB Test SWOT Analysis, 2013
- Table 17: Immuno-FOB Tests
- Table 18: Product Profile - Lateral Flow Immunochemical Fecal Occult Blood Tests
- Table 19: Lateral Flow Immunochemical Fecal Occult Blood Tests SWOT Analysis, 2013
- Table 20: Product Profile - Veda Lab Easy Reader (Lateral Flow Immunochemical Fecal Occult Blood Tests with Readers)
- Table 21: Veda Lab Easy Reader (Lateral Flow Immunochemical Fecal Occult Blood Tests with Readers) SWOT Analysis, 2013
- Table 22: Fecal Occult Blood ELISA Products
- Table 23: Product Profile - Fecal Occult Blood ELISA
- Table 24: Immuno-FOB Test ELISA SWOT Analysis, 2013
- Table 25: Commercially Available Immuno-FOB Agglutination Test Systems
- Table 26: Product Profile - Immuno-FOB Agglutination Tests
- Table 27: Immuno-FOB Agglutination Tests SWOT Analysis, 2013
- Table 28: Key Mutations Associated with CRC
- Table 29: Key Stages of PCR Gene Test
- Table 30: Product Profile - PreGen Plus
- Table 31: PreGen Plus SWOT Analysis, 2013
- Table 32: Product Profile - K-RAS, B-RAF, PIK3CA Array
- Table 33: K-RAS, B-RAF, PIK3CA Array SWOT Analysis, 2013
- Table 34: Product Profile - Colonsentry
- Table 35: Colonsentry SWOT Analysis, 2013
- Table 36: Product Profile - Detector C 2.0
- Table 37: Detector C SWOT Analysis, 2013

Table 38: Product Profile - ColoSure
Table 39: ColoSure SWOT Analysis, 2013
Table 40: Product Profile - MS9
Table 41: MS9 SWOT Analysis, 2013
Table 42: Septin-9 CRC Screening Marketed Laboratory-Developed Tests
Table 43: Product Profile - ColoVantage/Septin-9
Table 44: ColoVantage/Septin-9 SWOT Analysis, 2013
Table 45: Product Profile - Tumor M2-PK Stool Test/2-in-1 Quick Test
Table 46: Tumor M2-PK Stool Test/2-in-1 Quick Test SWOT Analysis, 2013
Table 47: Product Profile - Transferrin Assays
Table 48: Transferrin Assays SWOT Analysis, 2013
Table 49: Major Reasons for Non-compliance with CRC Screening
Table 50: Correlation of Fecal Occult Blood Test with Neoplasia
Table 51: CRC Screening Tests Pipeline, 2012
Table 52: Product Profile - BST1 CRC Assay
Table 53: BST1 CRC Assay SWOT Analysis, 2013
Table 54: Product Profile - Cologic
Table 55: Cologic SWOT Analysis, 2013
Table 56: Product Profile - ColoGuard
Table 57: ColoGuard SWOT Analysis, 2013
Table 58: Product Profile - Colon Cancer BEC Test
Table 59: Colon Cancer BEC Test SWOT Analysis, 2013
Table 60: Product Profile - Colon MarCare Plex
Table 61: Colon MarCare Plex SWOT Analysis, 2013
Table 62: Product Profile - Colox
Table 63: Colox SWOT Analysis, 2013
Table 64: Product Profile - CRC Bacterial Signature Assay
Table 65: CRC Bacterial Signature Assay SWOT Analysis, 2013
Table 66: Product Profile - CRC Breath Test
Table 67: CRC Breath Test SWOT Analysis, 2013
Table 68: Product Profile - Epi proColon
Table 69: Epi proColon Clinical Trials
Table 70: Epi proColon SWOT Analysis, 2013
Table 71: ExiQon MicroRNA Sensitivity and Specificity
Table 72: Product Profile - ExiQon microRNA Test
Table 73: ExiQon microRNA Test SWOT Analysis, 2013
Table 74: Product Profile - Gemini CRC Biomarker Assay
Table 75: Gemini CRC Biomarker Assay SWOT Analysis, 2013
Table 76: Product Profile - GenomicTree Methylated DNA Test
Table 77: GenomicTree Methylated DNA Test SWOT Analysis, 2013
Table 78: Product Profile - Measure
Table 79: Measure SWOT Analysis, 2013
Table 80: Product Profile - Metabionics CRC Test
Table 81: Metabionics CRC Test SWOT Analysis, 2013
Table 82: Product Profile - miR-21 Test
Table 83: miR-21 Test SWOT Analysis, 2013

Table 84: Product Profile - Oncolite-CR
Table 85: Oncolite-CR SWOT Analysis, 2013
Table 86: Product Profile - PanC-Dx
Table 87: PanC-Dx SWOT Analysis, 2013
Table 88: Key Mergers and Acquisitions during 2012-2013
Table 89: Company Profile - Abbott Molecular
Table 90: Abbott Molecular SWOT Analysis, 2013
Table 91: Company Profile - Alere
Table 92: Alere SWOT Analysis, 2013
Table 93: Company Profile - Beckman Coulter
Table 94: Beckman Coulter SWOT Analysis, 2013
Table 95: Company Profile - Biomarcare Technologies
Table 96: Biomarcare Technologies SWOT Analysis, 2013
Table 97: Company Profile - Companion Dx
Table 98: Companion Dx SWOT Analysis, 2013
Table 99: Company Profile - Eiken Chemical
Table 100: Eiken Chemical SWOT Analysis, 2013
Table 101: Company Profile - Epigenomics
Table 102: Epigenomics SWOT Analysis, 2013
Table 103: Company Profile - Exact Sciences
Table 104: Exact Sciences SWOT Analysis, 2013
Table 105: Company Profile - ExiQon
Table 106: ExiQon SWOT Analysis, 2013
Table 107: Company Profile - Fujirebio (Miraca Holdings)
Table 108: Fujirebio SWOT Analysis, 2013
Table 109: Company Profile - GeneNews
Table 110: GeneNews SWOT Analysis, 2013
Table 111: Company Profile - GenomicTree
Table 112: GenomicTree SWOT Analysis, 2013
Table 113: Company Profile - Immunostics
Table 114: Immunostics SWOT Analysis, 2013
Table 115: Company Profile - Kyowa Medex (Kyowa Hakko Kirin Group)
Table 116: Kyowa Medex SWOT Analysis, 2013
Table 117: Company Profile - MDx Health
Table 118: MDx Health SWOT Analysis, 2013
Table 119: Company Profile - Merck Millipore
Table 120: Merck Millipore SWOT Analysis, 2013
Table 121: Company Profile - Metabionics
Table 122: Metabionics SWOT Analysis, 2013
Table 123: Company Profile - Mode Diagnostics
Table 124: Mode Diagnostics SWOT Analysis, 2013
Table 125: Company Profile - Oncocyte (Bio Time)
Table 126: Oncocyte (Bio Time) SWOT Analysis, 2013
Table 127: Company Profile - Quest Diagnostics
Table 128: Quest Diagnostics SWOT Analysis, 2013
Table 129: Company Profile - R-Biopharm

Table 130: R-Biopharm SWOT Analysis, 2013
Table 131: Company Profile - Randox Laboratories
Table 132: Randox Laboratories SWOT Analysis, 2013
Table 133: Company Profile - ScheBo Biotech
Table 134: Schebo Biotech SWOT Analysis, 2013
Table 135: Company Profile - SciMarket Technologies
Table 136: SciMarket Technologies SWOT Analysis, 2013
Table 137: Company Profile - Siemens Healthcare
Table 138: Siemens Healthcare SWOT Analysis, 2013
Table 139: Company Profile - Signature Diagnostics
Table 140: Signature Diagnostics SWOT Analysis, 2013
Table 141: Company Profile - Sysmex
Table 142: Sysmex SWOT Analysis, 2013
Table 143: Company Profile - Veda Lab
Table 144: Veda Lab SWOT Analysis, 2013
Table 145: PreGen Plus Compared to Immuno-FOB Test
Table 146: Potential Impacts of Restriction of Gene Patents
Table 147: Major Events Affecting the EU In-Vitro CRC Screening Test Market
Table 148: Sales Forecasts for In-vitro CRC Screening Tests in the EU Markets, 2010-2019
Table 149: Forecasts for Numbers of In-vitro CRC Screening Tests within Europe, 2010-2019
Table 150: Sales Forecasts for In-vitro CRC Screening Tests in France, 2010-2019
Table 151: Sales Forecasts for In-vitro CRC Screening Tests in Germany, 2010-2019
Table 152: Sales Forecasts for In-vitro CRC Screening Tests in Italy, 2010-2019
Table 153: Sales Forecasts for In-vitro CRC Screening Tests in Spain, 2010-2019
Table 154: Sales Forecasts for In-vitro CRC Screening Tests in the UK, 2010-2019

1.2 List of Figures

Figure 1: Colorectal Cancer Staging
Figure 2: EU Trends in Colorectal Cancer Incidence, 2010-2019
Figure 3: Total Costs of Colorectal Cancer to Society, 2010-2019
Figure 4: Example of a Guaiac Fecal Occult Blood Card: Immunostics Hema-Screen
Figure 5: Fecal Occult Blood Test Lateral Flow Device Architecture
Figure 6: Biohit Colonview (example of immuno-FOB test)
Figure 7: Beckman Coulter Hemocult-ICT (example of immuno-FOB test)
Figure 8: Veda Labs Easy Reader Immuno-FOB Test LFD Reader
Figure 9: OC-Hemodia Agglutination FOB Test (manually performed)
Figure 10: OC-Sensor/Diana FOB Test Sample Cartridge
Figure 11: OC-Sensor/Diana FOB Test Instrument
Figure 12: Fujirebio HemSp/MagStream HT Magnetic Agglutination Reaction
Figure 13: Sentinel Diagnostic Sentifob Instrument
Figure 14: Alere CI5 NS-Plus Instrument
Figure 15: Orion Diagnostics Quikread FOB Test and Instrument
Figure 16: Basic PCR Process
Figure 17: MS9 PCR Response Curve

Figure 18: Proposed ColoGuard Patient Stool Sample Collection Kit
Figure 19: Exact Sciences Automated Sample Processing WorkStation
Figure 20: Colox Kit Contents
Figure 21: Measure Fecal Occult Blood Test
Figure 22: PanC-Dx Multiplex Detection of CRC-specific Biomarker
Figure 23: EU Sales Forecast for In-vitro CRC Screening Tests (\$m), 2010-2019
Figure 24: Forecast for Numbers of In-vitro CRC Screening Tests within Europe, 2010-2019
Figure 25: EU Share of Fecal Occult Blood Tests, by Brand, 2012
Figure 26: France Sales Forecast for In-vitro CRC Screening Tests (\$m), 2010-2019
Figure 27: Germany Sales Forecast for In-vitro CRC Screening Tests (\$m), 2010-2019
Figure 28: Italy Sales Forecast for In-vitro CRC Screening Tests (\$m), 2010-2019
Figure 29: Spain Sales Forecast for In-vitro CRC Screening Tests (\$m), 2010-2019
Figure 30: UK Sales Forecast for In-vitro CRC Screening Tests (\$m), 2010-2019